Exhibit 99.1
1 March 2018
Motif Bio plc
(“Motif Bio” or the “Company”)
Grant of share options to senior management
Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company has granted a total of 4,750,000 options to purchase ordinary shares of 1 pence each of Motif Bio (“Ordinary Shares”) under the Company’s 2015 share option plan. The options have an exercise price of 36.1 pence per Ordinary Share, being the closing price of the Ordinary Shares on February 28, 2018, the date of grant of the options.
Graham Lumsden, Chief Executive Officer, has been granted 3,000,000 options to purchase Ordinary Shares which vest over a four-year period, 2,000,000 of which are based on meeting certain performance targets. Jonathan Gold, Interim Chief Financial Officer, has been granted 1,000,000 options to purchase Ordinary Shares, 750,000 of which vest over a four-year period and are based on meeting certain performance targets and 250,000 of which will vest over a 12-month period beginning at the end of his interim assignment. Dr David Huang, Chief Medical Officer, was granted 750,000 options to purchase Ordinary Shares which vest over a four-year period.
For further information, please contact:
Motif Bio plc | info@motifbio.com |
Graham Lumsden (Chief Executive Officer) | |
| |
Peel Hunt LLP (NOMAD & BROKER) | + 44 (0)20 7418 8900 |
Dr Christopher Golden | |
Oliver Jackson | |
| |
Northland Capital Partners Limited (BROKER) | +44 (0)203 861 6625 |
David Hignell/John Howes/Rob Rees | |
| |
Walbrook PR Ltd. (UK FINANCIAL PR & IR) | +44 (0) 20 7933 8780 |
Paul McManus/Helen Cresswell/ | motifbio@walbrookpr.com |
Lianne Cawthorne | |
| |
MC Services AG (EUROPEAN IR) | +49 (0)89 210 2280 |
Raimund Gabriel | raimund.gabriel@mc-services.eu |
| |
The Trout Group (US IR) | + 1 (646) 378-2936 |
Meggie Purcell | mpurcell@troutgroup.com |
| |
Russo Partners (US PR) | +1 (858) 717-2310 |
| +1 (212) 845-4272 |
David Schull | david.schull@russopartnersllc.com |
Travis Kruse, Ph.D. | travis.kruse@russopartnersllc.com |
1. | Details of the person discharging managerial responsibilities / person closely associated |
| |
a. | Name | Graham Lumsden |
| | |
2. | Reason for the notification | |
| | |
a. | Position/status | Chief Executive Officer |
| | |
b. | Initial notification /Amendment | Initial |
| | |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| | |
a. | Name | Motif Bio plc |
| | |
b. | LEI | 54930080DN00QTIUUU84 |
| | |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| | |
a. | Description of the Financial instrument, type of instrument Identification code | Options over ordinary shares of 1p each GB00BVVT4H71 |
| | |
b. | Nature of the transaction | Grant of options to a PDMR |
| | |
c. | Price(s) and volume(s) | Price(s) | | Volume(s) | |
| | | | | |
| | 0p | | 3,000,000 | |
| | |
d. | Aggregated information · Aggregated volume · Price | N/A |
| | |
e. | Date of the transaction | 2018-02-28 |
| | |
f. | Place of the transaction | N/A |
| | |
5. | Details of the person discharging managerial responsibilities / person closely associated |
| | |
a. | Name | Jonathan Gold |
| | |
6. | Reason for the notification | |
| | |
a. | Position/status | Interim Chief Financial Officer |
| | |
b. | Initial notification /Amendment | Initial |
| | |
7. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| | |
a. | Name | Motif Bio plc |
| | |
b. | LEI | 54930080DN00QTIUUU84 |
| | |
8. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| | |
a. | Description of the Financial instrument, type of instrument Identification code | Options over ordinary shares of 1p each GB00BVVT4H71 |
2
b. | Nature of the transaction | Grant of options to a PDMR |
| | |
c. | Price(s) and volume(s) | Price(s) | | Volume(s) | |
| | | | | |
| | 0p | | 1,000,000 | |
| | |
d. | Aggregated information · Aggregated volume · Price | N/A |
| | |
e. | Date of the transaction | 2018-02-28 |
| | |
f. | Place of the transaction | N/A |
| | |
9. | Details of the person discharging managerial responsibilities / person closely associated |
| | |
a. | Name | Dr David Huang |
| | |
10. | Reason for the notification | |
| | |
a. | Position/status | Chief Medical Officer |
| | |
b. | Initial notification /Amendment | Initial |
| | |
11. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| | |
a. | Name | Motif Bio plc |
| | |
b. | LEI | 54930080DN00QTIUUU84 |
| | |
12. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| | |
a. | Description of the Financial instrument, type of instrument Identification code | Options over ordinary shares of 1p each GB00BVVT4H71 |
| | |
b. | Nature of the transaction | Grant of options to a PDMR |
| | |
c. | Price(s) and volume(s) | Price(s) | | Volume(s) | |
| | | | | |
| | 0p | | 750,000 | |
| | |
d. | Aggregated information · Aggregated volume · Price | N/A |
| | |
e. | Date of the transaction | 2018-02-28 |
| | |
f. | Place of the transaction | N/A |
3
